Drug Trial Radar · NCT00460525
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Last checked: Nov 20, 2026Latest source record: Nov 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
May 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- U.S. Army Medical Research and Development CommandFederal agency
- Sponsor type
- Federal agency
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Walter Reed Army Institute of Research (WRAIR); GlaxoSmithKline; University of Maryland
- First posted
- Apr 16, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 year, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria vaccine (FMP2.1/AS02A) to the number of children who get malaria after receiving a vaccine for rabies (an approved vaccine that does not prevent malaria). The children will be assigned to one of the vaccine groups by chance. Participants and doctors will not know which vaccine was given. Study participants will include 400 children, ages 1-6 years, living in Bandiagara, Mali. Children will receive 3 vaccine doses, by injection, to their upper arm. Study procedures will include physical exams and several blood samples. Participants will be involved in the study for 26 months.
Conditions
- Plasmodium Falciparum Malaria
Interventions
FMP2.1/AS02ABiological
3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
Rabies VaccineBiological
White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First VaccinationTime frame: 0-7 days after first vaccination
- Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.Time frame: 0-7 days after the second vaccination
- Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.Time frame: 0-7 days after the third vaccination
- Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First VaccinationTime frame: Day 0-29 after first vaccination
- Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second VaccinationTime frame: Day 0-29 after second vaccination
- Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third VaccinationTime frame: Day 0-29 after third vaccination
- Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.Time frame: Occurring between randomization and 6 months after the assigned date of the 3rd immunization.
- Number of Subjects Reporting Serious Adverse EventsTime frame: 24 months after initial vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Bamako, Malaria Research and Training Center
Bamako, Mali
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.